David Risinger

We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which David Risinger is associated, including Keytruda, Washington, and earnings. Most recently, David Risinger has been quoted saying: “Given recent earnings shortfalls and guidance reductions, we believe many investors want to see and assess 2017 guidance before building larger stock positions. The ability of management teams to regain investor confidence will be key to potentially better stock performance.” in the article Here are 3 top health-care stock ideas for 2017 from Morgan Stanley.

David Risinger quotes

Automatically powered by

We expect Merck to return to accelerating earnings growth in 2018 after six years of flat earnings driven by Keytruda growth as Merck builds on its leadership position in immuno-oncology. Our long term estimates are well above consensus.

Several factors are likely to drive industry performance, most important Washington pricing discussions, financial results, pipeline newsflow, tax reform, and transaction activity.

Given recent earnings shortfalls and guidance reductions, we believe many investors want to see and assess 2017 guidance before building larger stock positions. The ability of management teams to regain investor confidence will be key to potentially better stock performance.

No quotes...
More David Risinger quotes
|< <
{{currentQuotePage}}/{{numberPage}}
> >|
<
>